Alembic Pharma Q2 FY27: PAT +81%, US Sales +77% YoY

💊 Pharma results season just got interesting!

(Alembic Pharmaceuticals) hit the 20% upper circuit after its Q2 FY27 numbers. Here is what the quarter actually shows: ✅ Revenue ₹2,603 Cr, up 36% YoY ✅ EBITDA ₹578 Cr, up 78% YoY; margin 22.2% (up ~520 bps) ✅ PAT ₹335 Cr, up 81% YoY ✅ US formulations ₹1,003 Cr, up 77% YoY (39% of sales); base US portfolio ex-new launches grew 23% ✅ India branded ₹725 Cr (+14%), API ₹436 Cr (+39%), Animal health +23%, Ex-US +12% ✅ H1 FY27: revenue +31%, PAT +50%; net debt under 1x EBITDA ✅ Management raised FY27 revenue growth guidance to ~20–25% (from mid-teens), but expects US generics growth to cool to 10–12% in FY28 🔍 Key points to study: • How much of the US jump came from one product (bosutinib) vs the base portfolio • Whether high-teens EBITDA guidance means Q2's 22% margin may not repeat • India branded growth still below market — recovery timeline of 2–3 quarters A big one-product quarter can be a launchpad or a peak. 💬 What matters more to you here — the US surge or the India business turnaround? 📲 For daily market notes, search "Neha Gupta SEBI RA" on Telegram and join the FREE channel. Neha Gupta | SEBI Registered Research Analyst | Reg. No. INH000016542 ⚠️ Disclaimer: This content is for educational purposes only and is not investment advice or a buy/sell recommendation. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.